-
-
Topline results of Phase 1-2 CDNF trial
-
Posted in Industry News
-
07th Mar 2020
-
Industry news from Herantis Pharma
-
-
Brain Tumour Support: Sparkle up your day
-
Posted in Industry News
-
24th Feb 2020
-
Charity news from Brain Tumour Support
-
-
Dravet Syndrome UK – new professional advisors
-
Posted in Industry News
-
23rd Feb 2020
-
News from Dravet Syndrome UK
-
-
Epilepsy Research UK and Young Epilepsy – Joint Fellowship
-
Posted in Industry News
-
20th Feb 2020
-
Epilepsy Research UK (ERUK) and Young Epilepsy announce Joint Fellowship This unique research collaboration aims to improve epilepsy treatment for young people by addressing the causes, prevention and clinical management of childhood epilepsies. There are approximately 112,000 children and young people with epilepsy in the UK. Epilepsies that start in childhood can be linked with […]
-
-
Dementia Research: New Alzheimer Europe discussion paper
-
Posted in Industry News
-
19th Feb 2020
-
New discussion paper from Alzheimer Europe
-
-
USD $4.5 million co-funding agreement for Parkinson’s research announced
-
Posted in Industry News
-
13th Feb 2020
-
News from The Cure Parkinson’s Trust
-
-
SUNFISH Pivotal Results for Risdiplam (RG7916) Demonstrate Medically Meaningful Benefit in Broadest Age Group of Patients Studied with Type 2 and 3 Spinal Muscular Atrophy
-
Posted in Industry News
-
10th Feb 2020
-
Industry news from PTC therapeutics
-
-
Data highlights need for more preventative care for MS patients
-
Posted in Industry News
-
10th Feb 2020
-
Service News: hospital admissions for MS patients on the rise.
-
-
First Publication of Real-World Data Showing Translarna (ataluren) Significantly Preserves Ability to Walk for Longer in Children with Duchenne Muscular Dystrophy
-
Posted in Industry News
-
05th Feb 2020
-
Industry news from PTC Therapeutics
-
-
Type 1 Spinal Muscular Atrophy: Risdiplam (RG7916) Pivotal FIREFISH Study Demonstrated Statistically Significant Improvement in Infants
-
Posted in Industry News
-
23rd Jan 2020
-
News from PTC therapeutics